Overcoming some hurdles remain in the broad application of nonviral delivery, however, we are confident that we will successfully accomplish the remaining challenges soon. Furthermore, we predict that eventually the majority of gene therapies will use artificial reagents that can be standardized and regulated as drugs rather than biologics. We will continue to incorporate the molecular mechanisms of viral delivery that produce efficient delivery to cells into artificial systems. Therefore, the artificial systems, including liposomal delivery vehicles, will be further engineered to mimic the most beneficial parts of the viral delivery systems while circumventing their limitations. We will also maintain the numerous benefits of the liposomal delivery systems discussed in this chapter.

0 0

Post a comment